Press release
GLP-1 Market Set to Surge, Reaching USD 187.2 Billion by 2034 at 16.2% CAGR
GLP-1 Market
The glucagon-like peptide-1 (GLP-1) receptor agonist market has rapidly emerged as one of the most transformative segments of the pharmaceutical industry. Initially developed for type 2 diabetes management, GLP-1 drugs are now widely recognized for their dual benefits in glycemic control and weight management.
The surge in global obesity and diabetes prevalence, combined with strong clinical outcomes and regulatory approvals, has made GLP-1 therapies a blockbuster category. By 2024, the GLP-1 market size is estimated at USD 40.5 billion and is projected to reach USD 187.2 billion by 2034, expanding at a CAGR of 16.2% during 2025-2034.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72406
Market Overview
Key highlights of the global GLP-1 market:
• Market Size 2024: USD 40.5 billion
• Forecast 2034: USD 187.2 billion
• CAGR (2025-2034): ~16.2%
• Key Drivers: Rising prevalence of type 2 diabetes and obesity, expanding therapeutic applications, growing acceptance of GLP-1s in weight management, and robust R&D pipelines.
• Challenges: High treatment costs, supply shortages due to surging demand, and limited access in developing countries.
• Leading Players: Novo Nordisk (Ozempic, Wegovy), Eli Lilly (Mounjaro, Trulicity), Pfizer, Amgen, AstraZeneca, Sanofi, Johnson & Johnson, Merck & Co., Boehringer Ingelheim, and Hanmi Pharmaceutical.
The market is dominated by Novo Nordisk and Eli Lilly, whose GLP-1 portfolios are transforming diabetes and obesity treatment worldwide.
Segmentation Analysis
By Drug Type
• Semaglutide (Ozempic, Wegovy, Rybelsus)
• Tirzepatide (Mounjaro, Zepbound - dual GIP/GLP-1)
• Dulaglutide (Trulicity)
• Liraglutide (Victoza, Saxenda)
• Exenatide (Byetta, Bydureon)
• Others (Pipeline Drugs, Biosimilars)
By Route of Administration
• Injectable GLP-1s
• Oral GLP-1s
By Application
• Type 2 Diabetes
• Obesity & Weight Management
• Cardiovascular Diseases
• Other Metabolic Disorders
By End User
• Hospitals & Clinics
• Retail Pharmacies
• Online Pharmacies
Summary:
Injectable GLP-1s dominate, but oral formulations like Rybelsus are gaining traction for their convenience. Beyond diabetes, obesity and cardiovascular applications represent the fastest-growing segments.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72406/glp-1-market
Regional Analysis
North America
• Largest market due to high diabetes and obesity prevalence, strong reimbursement systems, and rapid adoption of novel GLP-1 drugs.
• The U.S. leads globally, with Novo Nordisk and Eli Lilly driving blockbuster sales.
Europe
• Strong growth in Germany, the UK, and France, supported by healthcare coverage and expanding obesity management programs.
• EU regulatory approvals and favorable guidelines fuel adoption.
Asia-Pacific
• Expected to record the fastest CAGR through 2034, driven by rising diabetes prevalence in India and China, growing obesity rates, and expanding healthcare access.
• Japan and South Korea are also key innovation hubs.
Middle East & Africa
• Rising adoption in Gulf countries like Saudi Arabia and UAE due to growing obesity prevalence.
• Limited access and affordability remain challenges in many African nations.
Latin America
• Brazil and Mexico lead adoption, supported by growing obesity and diabetes cases and gradual expansion of GLP-1 accessibility.
Summary:
North America dominates today, but Asia-Pacific will post the fastest growth, thanks to the rising healthcare burden of diabetes and obesity combined with expanding healthcare infrastructure.
Market Dynamics
Key Growth Drivers
• Increasing prevalence of type 2 diabetes and obesity worldwide.
• Expansion of GLP-1s into weight management and cardiovascular disease treatment.
• Strong R&D pipeline with next-generation dual and triple agonists.
• Growing awareness and acceptance of GLP-1s among healthcare professionals and patients.
• Government initiatives to address obesity and diabetes as public health priorities.
Key Challenges
• High cost of GLP-1 therapies, limiting accessibility in developing markets.
• Ongoing supply shortages due to surging demand.
• Side effects such as nausea and gastrointestinal discomfort.
• Competitive pressures from biosimilars and upcoming therapies.
Latest Trends
• Launch of dual and triple incretin agonists (GLP-1/GIP, GLP-1/glucagon).
• Integration of digital health and remote monitoring for patient adherence.
• Expansion of oral GLP-1 formulations for improved compliance.
• Strategic partnerships between pharma companies to expand production capacity.
• Use of GLP-1s in new therapeutic areas like NASH (nonalcoholic steatohepatitis).
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72406
Competitor Analysis
Major Players
• Novo Nordisk - Market leader with Ozempic, Wegovy, Rybelsus, and Saxenda.
• Eli Lilly - Fast-growing with Mounjaro (tirzepatide) and Trulicity.
• Pfizer - Developing oral GLP-1 therapies.
• Amgen - Advancing pipeline in metabolic disorders.
• AstraZeneca - Expanding diabetes and obesity drug portfolio.
• Sanofi - Strengthening metabolic disease therapeutics.
• Johnson & Johnson - Exploring GLP-1 applications in obesity management.
• Merck & Co. - Focused on diabetes care expansion.
• Boehringer Ingelheim - Active in incretin-based therapies.
• Hanmi Pharmaceutical - Innovating in long-acting GLP-1 analogs.
Summary:
The market is dominated by Novo Nordisk and Eli Lilly, whose GLP-1 drugs are global blockbusters. However, intense competition is building with pipeline entrants and biosimilars expected to reshape market dynamics by 2030.
Conclusion
The GLP-1 market is set for explosive growth, expanding from USD 40.5 billion in 2024 to USD 187.2 billion by 2034, at a CAGR of 16.2%.
Key Takeaways:
• GLP-1s are expanding beyond diabetes into obesity and cardiovascular disease.
• Injectable formulations dominate, but oral drugs are gaining momentum.
• North America leads, while Asia-Pacific will be the fastest-growing region.
• Next-generation incretin therapies and production scale-up will define the future.
This report is also available in the following languages : Japanese (GLP-1市場), Korean (GLP-1 시장), Chinese (GLP-1市场), French (Marché du GLP-1), German (GLP-1-Markt), and Italian (Mercato GLP-1), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72406
Our More Reports:
EZH2 Inhibitors Market
https://exactitudeconsultancy.com/reports/72430/ezh2-inhibitors-market
Genotoxicity Testing Market
https://exactitudeconsultancy.com/reports/72432/genotoxicity-testing-market
Quality Control and Regulation in Medical Devices Market
https://exactitudeconsultancy.com/reports/72434/quality-control-and-regulation-in-medical-devices-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GLP-1 Market Set to Surge, Reaching USD 187.2 Billion by 2034 at 16.2% CAGR here
News-ID: 4198286 • Views: …
More Releases from Exactitude Consultancy
Sterile Injectable Contract Manufacturing Market to Reach USD 72.6 Bn by 2034 at …
Introduction
The global demand for sterile injectable drugs has surged, driven by the increasing prevalence of chronic and infectious diseases, the rise of biologics, and the growing emphasis on targeted therapies. As pharmaceutical companies face pressure to accelerate time-to-market and manage costs, contract manufacturing organizations (CMOs) have emerged as crucial partners in sterile injectable production.
Sterile injectable contract manufacturing ensures compliance with stringent regulatory requirements, advanced aseptic processing, and scalability for both…
Monoclonal Antibodies in Veterinary Health Market to Reach USD 2.5 Bn by 2034
Introduction
The adoption of monoclonal antibodies (mAbs) in veterinary health represents a groundbreaking advancement in animal medicine. Once primarily associated with human healthcare, mAbs are now being developed for companion and livestock animals to treat conditions such as cancer, infections, and chronic inflammatory diseases. Their ability to target specific antigens with precision makes them one of the most promising therapeutic modalities for animal health.
As pet ownership rises globally and demand for…
Hair Transplant Market Set to Surge, Reaching USD 25.9 Billion by 2034 at 13.6% …
Introduction
Hair loss, or alopecia, affects millions of people globally and has significant psychological and social implications. While topical treatments and oral medications remain common, hair transplant procedures have emerged as the most effective long-term solution for restoring natural hair growth.
Technological advancements such as robotic-assisted surgery, minimally invasive techniques, and platelet-rich plasma (PRP) therapy have made hair restoration more accessible and effective. By 2024, the hair transplant market size is estimated…
BRIC Non-Vascular Stents Market Forecasted to Reach USD 1.4 Billion by 2034
The global healthcare industry is evolving rapidly, with innovative medical devices transforming patient outcomes and redefining standards of care. One such device gaining remarkable traction is the non-vascular stent-an implantable medical device used to maintain the patency of non-vascular luminal structures such as the biliary duct, esophagus, trachea, colon, and urinary tract. In the BRIC region (Brazil, Russia, India, China), the non-vascular stents market is experiencing accelerated growth, driven by…
More Releases for USD
Chlorella Market Reach USD 465.85 Million USD by 2030
Market Growth Fueled by Increased Adoption of Plant-Based Proteins and Health Supplements
Global Chlorella Market size was valued at USD 303.75 Mn. in 2023 and the total Chlorella revenue is expected to grow by 6.3 % from 2024 to 2030, reaching nearly USD 465.85 Mn. . The growth of the market is majorly due to increase in the consumer awareness about health, the inclination towards plant-based food such as chlorella and…
Bamboo Clothing Market: USD 1.83B to USD 3.27B by 2030
Bamboo Clothing Market Poised for Robust Growth with Sustainability and Eco-Friendly Trends Driving Demand
The global bamboo clothing market is experiencing substantial growth, spurred by a significant shift towards sustainable fashion and eco-friendly materials. As consumers become increasingly conscious of their environmental impact, bamboo fabric-known for its natural, biodegradable properties-is gaining popularity in the fashion industry. This market is expected to continue its upward trajectory, driven by rising demand for eco-conscious…
Biometrics Market: "Biometrics: USD 34.3B to USD 112.4B by 2031"
Biometrics Market Market Scope:
Key Insights : Biometrics Market size was valued at USD 34.3 billion in 2022 and is poised to grow from USD 39.1 billion in 2023 to USD 112.4 billion by 2031, growing at a CAGR of 14.1% during the forecast period (2024-2031).
Discover Your Competitive Edge with a Free Sample Report :https://www.skyquestt.com/sample-request/biometrics-market
Access the full 2024 Market report for a comprehensive understanding @https://www.skyquestt.com/report/biometrics-market
In-Depth Exploration of the global Biometrics…
Advanced (3D/4D) Visualization Systems Market Size, Trends, Growth, Share to sur …
Fatpos Global has carefully studied specific areas, such as application and product type, in the global Advanced (3D/4D) Visualization Systems Market research study. During the predicted period of 2022 to 2032, each kind gives data on sales. The Advanced (3D/4D) Visualization Systems Market analysis examines into the characteristics and financials of the leading participants.
As per the analysis research report, the Advanced (3D/4D) Visualization Systems Market to…
$100,000,000 USD job contract for travel - $3,000,000 USD referral commission.
Khoja Consultants invites companies, teams or venture capitalists for a $100,000,000 USD contract for travel. The selected company will be providing all accommodations and expenses for a 6-month long business trip around the world. Khoja Consultants expects five-star treatment including close security with private planes, hotels, secured vehicles and helicopters if necessary. More details on the job contract and application are provided at - www.KhojaConsultants.com.
There is a $3,000,000…
IOT Solutions Market worth USD 553.9 million USD by 2026
"The global IoT solutions market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of cybersecurity as a service market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa."
These days many businesses are adopting a market research report…
